S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
AMD Results Are No Reason To Buy Semiconductors... Yet
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Bed Bath & Beyond Is Circling the Drain
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
AMD Results Are No Reason To Buy Semiconductors... Yet
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Bed Bath & Beyond Is Circling the Drain
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
AMD Results Are No Reason To Buy Semiconductors... Yet
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Bed Bath & Beyond Is Circling the Drain
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
AMD Results Are No Reason To Buy Semiconductors... Yet
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Bed Bath & Beyond Is Circling the Drain
Institutions are Buying up Procter & Gamble Shares, Should you?
NASDAQ:HQY

HealthEquity - HQY Price Target & Analyst Ratings

$58.99
-1.86 (-3.06%)
(As of 02/1/2023 12:00 AM ET)
Add
Compare
Today's Range
$58.88
$61.50
50-Day Range
$56.64
$67.73
52-Week Range
$50.35
$79.20
Volume
1.15 million shs
Average Volume
698,911 shs
Market Capitalization
$4.99 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$81.54

HealthEquity Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 10 Analyst Ratings

Consensus Analyst Price Target

$81.54
38.22% Upside
High Prediction$101.00
Average Prediction$81.54
Low Prediction$70.00
TypeCurrent
2/2/22 to 2/2/23
1 Month Ago
1/3/22 to 1/3/23
3 Months Ago
11/4/21 to 11/4/22
1 Year Ago
2/2/21 to 2/2/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
8 Buy rating(s)
11 Buy rating(s)
9 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$81.54$81.23$77.64$74.00
Predicted Upside38.22% Upside21.95% Upside20.32% Upside20.82% Upside
Get HealthEquity Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for HQY and its competitors with MarketBeat's FREE daily newsletter.


HQY Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HQY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

HealthEquity Stock vs. The Competition

TypeHealthEquityMedical CompaniesS&P 500
Consensus Rating Score
2.80
2.65
2.46
Consensus RatingModerate BuyBuyHold
Predicted Upside38.22% Upside1,302.23% Upside8.14% Upside
News Sentiment RatingPositive News
Positive News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/24/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$68.00 ➝ $72.00+27.32%
12/12/2022Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$75.00+19.73%
12/12/2022Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$75.00 ➝ $85.00+35.96%
12/7/2022Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$89.00 ➝ $94.00+43.14%
12/7/2022Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$104.00 ➝ $101.00+53.80%
12/5/2022Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$70.00 ➝ $75.00+14.47%
11/2/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$80.00 ➝ $90.00+14.65%
10/21/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeSell ➝ Neutral$64.00 ➝ $77.00+4.08%
9/15/2022KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$85.00+16.93%
6/7/2022Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$70.00 ➝ $75.00+14.75%
6/7/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$67.00 ➝ $76.00+15.98%
3/30/2022BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$85.00+27.02%
3/23/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$63.00 ➝ $70.00+20.38%
12/21/2021JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$82.00 ➝ $56.00+34.42%
7/1/2021Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$100.00+23.32%
6/8/2021Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Halper
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight$82.00 ➝ $85.00+3.27%
2/9/2021Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$80.00 ➝ $92.00+7.54%
3/26/2020SunTrust Banks
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$55.00 ➝ $68.00+21.17%
(Data available from 2/2/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












HQY Price Target - Frequently Asked Questions

What is HealthEquity's consensus rating and price target?

According to the issued ratings of 10 analysts in the last year, the consensus rating for HealthEquity stock is Moderate Buy based on the current 2 hold ratings and 8 buy ratings for HQY. The average twelve-month price prediction for HealthEquity is $81.54 with a high price target of $101.00 and a low price target of $70.00. Learn more on HQY's analyst rating history.

Do Wall Street analysts like HealthEquity more than its competitors?

Analysts like HealthEquity more than other Medical companies. The consensus rating for HealthEquity is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how HQY compares to other companies.

Does HealthEquity's stock price have much upside?

According to analysts, HealthEquity's stock has a predicted upside of 23.62% based on their 12-month price targets.

What analysts cover HealthEquity?

Stock Ratings Reports and Tools

This page (NASDAQ:HQY) was last updated on 2/2/2023 by MarketBeat.com Staff